CPHI [CHINA PHARMA] DEF 14A:
[]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Biotech Announces Receipt of Delisting Determination Letter from Nasdaq BEIJING, November 3, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA)(”Sinovac”), a leading provider of biopharmaceutical products in China, announced today that on November 1, 2017, the Company received a delisti]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Biotech Announces Receipt of Delisting Determination Letter
[Sinovac Biotech Announces Receipt of Delisting Determination Letter from Nasdaq BEIJING, November 3, 2017 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA)(”Sinovac”), a leading provider of biopharmaceutical products in China, announced today that on November 1, 2017, the Company received a delisti]
CPHI [CHINA PHARMA] 8-K: (Original Filing)
[Contact: China Pharma Holdings, Inc. Ms. Diana Na Huang Phone: +86-898-6681-1730 (China) Email: hps@chinapharmaholdings.com China Pharma Holdings, Inc. Announces Notification of NYSE American Listing Deficiency About China Pharma Holdings, Inc. Based in Haikou, Hainan Province, China, China Pharma H]
CPHI [CHINA PHARMA] 8-K: Contact: China Pharma Holdings, Inc. Ms. Diana Na
[Contact: China Pharma Holdings, Inc. Ms. Diana Na Huang Phone: +86-898-6681-1730 (China) Email: hps@chinapharmaholdings.com China Pharma Holdings, Inc. Announces Notification of NYSE American Listing Deficiency About China Pharma Holdings, Inc. Based in Haikou, Hainan Province, China, China Pharma H]
BSPM [Biostar Pharmaceuticals] 8-K: (Original Filing)
[Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice XIANYANG, China, August 28, 2017 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on August 22,]
BSPM [Biostar Pharmaceuticals] 8-K: Biostar Announces Receipt of Nasdaq Continued Listing Deficiency
[Biostar Announces Receipt of Nasdaq Continued Listing Deficiency Notice XIANYANG, China, August 28, 2017 – Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China, announced today that on August 22,]
BSPM [Biostar Pharmaceuticals] NT 10-Q: (Original Filing)
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 o o o (Check One): x o o For Period Ended: June 30, 2017 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein]
